| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WHITEHOUSE STATION, N.J.— The Antiviral Drugs AdvisoryCommittee of the U.S. Food and Drug Administration (FDA) has voted unanimously18-0 that the available data provided by Merck (known as MSD outside the UnitedStates and Canada) for its investigational medicine VICTRELIS (boceprevir)support approval of the medicine. VICTRELIS is meant for the treatment ofchronic hepatitis C virus (HCV) genotype 1 infection in combination with currentstandard therapy.
 
"We're pleased with the panel's decision and look forward toworking with the FDA as it continues to evaluate the application forVICTRELIS," says Peter Kim, Ph.D., president of Merck Research Laboratories.
 
 
The FDA will consider the committee's recommendation whenits reviews the New Drug Application for VICTRELIS. The FDA has grantedVICTRELIS with priority review status, which is reserved for investigationaldrugs that address significant unmet medical needs. Merck is anticipating FDAaction on the drug by mid-May. Similarly, the Marketing AuthorizationApplication for VICTRELIS has been accepted for accelerated assessment by theEuropean Medicines Agency.
 
 
VICTRELIS is an HCV protease inhibitor, a new class ofmedicines that is being evaluated for treating hepatitis C in patients who havenot undergone treatment previously or who have failed previous therapy.
 
 
The data reviewed by the panel came from the Phase IIIclinical study program for the drug, and the clinical trials HCV SPRINT-2 andHCV RESPOND-2 included about 1,500 patients with chronic HCV genotype 1, whichis the most common form of hepatitis in the U.S. and most difficult form totreat. The results from the two trials were published in the March 31 issue ofthe New England Journal of Medicine.
 
 
"The positive recommendation brings us one step closer tobringing VICTRELIS to men and women who need it, and reinforces our ongoingcommitment to developing innovative therapies to treat chronic hepatitis C,"says Kim. 
 
The need for new treatment is obvious, as about 170 millionpeople worldwide, 3.2 million of those in the U.S., suffer from chronichepatitis C, and no vaccine exists for the virus. Additionally, Merck reportedin a briefing document for the FDA that the current standard therapy thattreats the most common strain of hepatitis C consists of 48 weeks of treatmentand cures less than half of patients.
 
 
Merck's study discovered that when combined with standardtherapy, VICTRELIS cured 63 percent of patients with hepatitis C who had failedprevious treatments, as opposed the 23 percent that were cured with thestandard therapy alone. Additionally, of those patients who were new totreatment, 65 percent of who dosed with VICTRELIS were cured, compared to the38 percent of those treated with the standard therapy.
 
 
Given that those who were previously treated for hepatitis Cand failed to respond to VICTRELIS weren't included in Merck's trials,panelists recommended that the FDA require a caution in the drug's label,notifying users that it hasn't been studied in "null responders." Panel membersalso recommended that post-marketing studies of those patients, as well aspeople with HIV, organ transplant recipients and those taking durgs such asantidepressants, should be required.
 
"Itchanges the game completely and hopefully continues to advance the field," saysVictoria Cargill, the acting chairwoman of the Antiviral Drugs AdvisoryCommittee and director of minority research at the National Institutes ofHealth Office of AIDS Research in Bethesda, Md.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue